

Is Acetazolamide Still the Best Option?

- A Retrospective Review to Identify the Optimal Approach for Preventing Acute Mountain Sickness -



AMSA Japan

Miyuka Kushibe*, Hibiki Yamazaki,

Riko Shima, Ayuna Mizuno, Keigo Sano,

Kotomi Okita, Yudai Kaneda


Faculty of Medicine, University of Debrecen*

rcjapan@amsa-international.org*

Nepal is way above other countries

Kathmandu
1400m

Nepal
3625m (Avg)



If you have headache, fatigue.... might be AMS (Acute Mountain Sickness)!!?



Common in **rapid ascent**
to altitude **greater than 2500m**

Symptoms

Headache



Fatigue



Breathlessness



Sleep Disturbance



Vomiting and Nausea



Improvement areas of Acetazolamide

1. Other complicated mechanisms have been proposed

- A. Improvements in ventilation from tissue respiratory acidosis by \uparrow CCR
- B. Improvements in sleep quality from carotid body CA inhibition
- C. Diuresis effect in AMS is not well established

2. Poor availability

- A. Use of prophylactic AMS is not covered by insurance
- B. Prescription is required



Is Acetazolamide Still the Best Option?

Ibuprofen?

Ginkgo Biloba?

Dexamethasone?

Objective

Compare the efficacy and side effects of dexamethasone, ibuprofen and ginkgo biloba to acetazolamide



Evaluate the optimal medication for acute mountain sickness



Method

Search in Pubmed

2005-2022

Keywords :

AMS

Prevention

Acetazolamide

Dexamethasone

Ibuprofen

Ginkgo Biloba


Gather information

On
pharmacological
measures' efficacy
on the prevention
of AMS

Evaluate the efficacy


Descriptive
statistics

The number of published articles



Results -Incidence rate


The incidence of AMS was best prevented by Dexamethasone!



	Median
Acetazolamide	36%
Dexamethasone	30%
Ibuprofen	34%
Ginkgo Biloba	33%

Results - Side Effects

Acetazolamide



Dexamethasone

Not mentioned (by the method)

Ibuprofen


No major adverse events

Ginkgo Biloba



Discussion

Which drug is suitable?



Discussion 1 - Risk factors -

○ Low risk

	Acetazolamide	Dexamethasone	Ibuprofen	Ginkgo Biloba
Diabetes Mellitus			△	?
Pregnancy, Infants	○			○
Hypertension	○			○
Bleeding disorder	○	○		
NSAIDs, Aspirin allergy	○	○		
Liver and renal diseases		○	○	○
Respiratory disorders		○	○	○

Discussion 2 - Side effects -

Dose	AMS	Side effects
Low	↑	↓
High	↓	↑

Ibuprofen < **Acetazolamide** < **Dexamethasone**

*¹ Severeness and incidence

*² Insufficient data on side effects of **Ginkgo Biloba**

Discussion 3 - Others -

	Pros	Cons
Acetazolamide	Assist with acclimatization Lower risk for gastrointestinal symptoms	Lower availability Unrevealed mechanism
Dexamethasone	Safe for Sulfa allergy Used for any degree of AMS	Does not facilitate acclimatization
Ibuprofen	Better availability (OTC) Quick effect	Does not facilitate acclimatization (ventilatory) Mask headache → misdiagnosis
Ginkgo Biloba	OTC	Inconsistent effect Undefined effective dose

Discussion 4

All things considered...

Western medicine


-Acetazolamide

-Dexamethasone

-Ibuprofen

Contain only **one** kind of active ingredient

→The pharmacological effect can only be expected from that **ingredient alone**



Combination

Eastern medicine

-Ginkgo Biloba

Made by

combining a **variety** of crude drugs

and utilizing their pharmacological actions and interactions

Discussion 5

All things considered...

Mild AMS

Ginkgo Biloba × **Acetazolamide**

Mild or Severe AMS

Ginkgo Biloba × **Dexamethasone**

Prevention < Treatment

Ginkgo Biloba × **Ibuprofen**

Western medicine

-**Acetazolamide**

-**Dexamethasone**

-**Ibuprofen**



Combination

The best of both

Eastern medicine

-**Ginkgo Biloba**

- Treat side effects of western medicine
- Lower the dose of western medicine
→ Less side effect
- Synergy

Strengths

- Our research material includes latest articles that were published between 2005 and 2022
- **Coverage** of the results is high

Limitations

- Drugs efficacy depends on multiple factors
→ But **not taken into account** in this research
- Total number of data about the drugs' efficacy → **low**
- Effectiveness of each drug was evaluated individually

Conclusion

- The **incidence** of AMS

Dexamethasone < **Ginkgo Biloba** < **Ibuprofen** < **Acetazolamide**

- A **combination** of drugs may be more effective

Recommendation

- Investigation of **mechanism** may lead to **diminished side effects**
- Study taking into account the **limitations**
- Analysis of **combination**
- High altitude research can be also applied in **hypoxia associated diseases** in **low altitudes**

Acknowledgements and Conflict of Interest

Acknowledgements

- We would like to acknowledge AMSA Nepal for organizing this academic competition!

Conflict of interest

- None



References

- Swenson ER. Pharmacology of acute mountain sickness: old drugs and newer thinking. *J Appl Physiol* (1985). 2016;120(2):204-15.
- Leaf DE, Goldfarb DS. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. *J Appl Physiol* (1985). 2007;102(4):1313-22.
- Hussain MM, Aslam M, Khan Z. Acute mountain sickness score and hypoxemia. *J Pak Med Assoc.* 2001;51(5):173-9.
- Nieto Estrada VH, Molano Franco D, Medina RD, Gonzalez Garay AG, Marti-Carvajal AJ, Arevalo-Rodriguez I. Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs. *Cochrane Database Syst Rev.* 2017;6(6):CD009761.
- Murdoch D. Altitude sickness. *BMJ Clin Evid.* 2010;2010.
- Schmickl CN, Owens RL, Orr JE, Edwards BA, Malhotra A. Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence. *BMJ Open Respir Res.* 2020;7(1).
- Gao D, Wang Y, Zhang R, Zhang Y. Efficacy of acetazolamide for the prophylaxis of acute mountain sickness: A systematic review, meta-analysis, and trial sequential analysis of randomized clinical trials. *Ann Thorac Med.* 2021;16(4):337-46.
- Zafren K. Does ibuprofen prevent acute mountain sickness? *Wilderness & Environmental Medicine.* 2012;23(4):297-9.
- Lipman GS, Kanaan NC, Holck PS, Constance BB, Gertsch JH, Group P. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories. *Ann Emerg Med.* 2012;59(6):484-90.
- Xiong J, Lu H, Wang R, Jia Z. Efficacy of ibuprofen on prevention of high altitude headache: A systematic review and meta-analysis. *PLoS One.* 2017;12(6):e0179788.
- Basaran KE, Villongco M, Ho B, Ellis E, Zarndt R, Antonova J, et al. Ibuprofen Blunts Ventilatory Acclimatization to Sustained Hypoxia in Humans. *PLoS One.* 2016;11(1):e0146087.
- Pandit A, Karmacharya P, Pathak R, Giri S, Aryal MR. Efficacy of NSAIDs for the prevention of acute mountain sickness: a systematic review and meta-analysis. *J Community Hosp Intern Med Perspect.* 2014;4(4).
- Eide RP, 3rd, Asplund CA. Altitude illness: update on prevention and treatment. *Curr Sports Med Rep.* 2012;11(3):124-30.
- Gertsch JH, Corbett B, Holck PS, Mulcahy A, Watts M, Stillwagon NT, et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. *Wilderness Environ Med.* 2012;23(4):307-15.
- Wright AD, Birmingham Medical Research Expeditionary S. Medicine at high altitude. *Clin Med (Lond).* 2006;6(6):604-8.
- Allemann Y, Scherrer U. High-altitude medicine: important for trekkers and mountaineers, essential for progress in medicine. *Prog Cardiovasc Dis.* 2010;52(6):449-50.
- Carod-Artal FJ. Cefalea de elevada altitud y mal de altura. *Neurología.* 2014 Nov 1;29(9):533–40.
- Shlim DR. The use of acetazolamide for the prevention of high-altitude illness. *Journal of Travel Medicine.* 2020 Jan 2;27(6).
- Taylor A. High-altitude illnesses: Physiology, risk factors, prevention, and treatment. *Rambam Maimonides Medical Journal.* 2011 Jan 21;2(1).
- Prince TS, Thurman J, Huebner K. Acute Mountain Sickness. PubMed. Treasure Island (FL): StatPearls Publishing; 2020.
- Hussain MM, Aslam M, Khan Z. Acute mountain sickness score and hypoxemia. *JPMA The Journal of the Pakistan Medical Association.* 2001 May 1;51(5):173–9.

Authors



Miyuka Kushibe
Author, Presenter



Hibiki Yamazaki
Author



Riko Shima
Author, Presenter



Ayuna Mizuno
Author, Presenter



Keigo Sano
Author



Kotomi Okita
Author



Yudai Kaneda
Author



Thank you